Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 85 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Islet Cell Transplant Clear all
Completed Phase 1 Interventional

Treatment of Type I Diabetes by Islet Transplantation Into the Gastric Submucosa Study Protocol

NCT02402439
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet cells, Islet transplantation into the gastrointestinal submucosa
Drug · Procedure
Lead sponsor
Chuck Rickert, MD, PhD
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 9:15 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatment of Chronic Pancreatitis and Benign Pancreatic Tumors

NCT05453851
View directory record Official record
Conditions
Benign Pancreatic Neoplasm, Chronic Pancreatitis, Recurrent Acute Pancreatitis
Interventions
Pancreatectomy, Quality-of-Life Assessment, Treatment Planning
Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 17, 2026, 9:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Islet Transplantation for Type 1 Diabetes Mellitus

NCT00437398
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet Transplant
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Oct 17, 2026, 9:15 AM EDT
Completed Phase 2 Interventional Results available

Islet Transplantation for Type 1 Diabetes

NCT00014911
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
Islet Transplantation, Sirolimus, Tacrolimus, Daclizumab, Sulfamethoxazole, Ganciclovir, Trimethoprim, Pentamidine
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 17, 2026, 9:15 AM EDT
Completed No phase listed Observational

Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation

NCT02004964
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 17, 2026, 9:15 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation

NCT03513939
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sernova Cell Pouch
Combination Product
Lead sponsor
Sernova Biotherapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 17, 2026, 9:15 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of PEG-Encapsulated Islet Allografts Implanted in Type I Diabetic Recipients

NCT00260234
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Allogeneic Cultured Islet Cells (human); Encapsulated
Biological
Lead sponsor
Novocell
Industry
Eligibility
20 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 17, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 17, 2026, 9:15 AM EDT
Terminated Phase 1 Interventional

Islet Cell Transplants for Diabetes

NCT00303134
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet Cell Transplantation
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 17, 2026, 9:15 AM EDT
Not listed No phase listed Observational

Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant

NCT03415139
View directory record Official record
Conditions
Diabetes Mellitus, Cancer
Interventions
Oral Glucose Tolerance Test (OGTT), 2 OGTTs with and without GLP-1 analogue, Hyperglycemic clamp procedure
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 17, 2026, 9:15 AM EDT
Terminated Phase 2 Interventional Results available

Nitrite Infusion in Islet Cell Transplantation

NCT03544242
View directory record Official record
Conditions
Diabetes
Interventions
Control, Pre-Isolation Infusion, Post-Isolation Infusion
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 17, 2026, 9:15 AM EDT
Recruiting No phase listed Observational

The T1D Exchange Registry

NCT04629586
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes, Type 1 Diabetes, Diabetes Mellitus
Interventions
No intervention
Other
Lead sponsor
T1D Exchange, United States
Other
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 17, 2026, 9:15 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation

NCT01817959
View directory record Official record
Conditions
Islet Transplantation in Diabetes Mellitus Type 1
Interventions
Reparixin, Placebo
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 17, 2026, 9:15 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Islet After Kidney Transplant for Type 1 Diabetes

NCT00784966
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
etanercept
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 17, 2026, 9:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Breakthrough - T1DM and Chronic Kidney Disease

NCT07592000
View directory record Official record
Conditions
Diabete Type 1, Chronic Kidney Disease
Interventions
Tegoprubart, Islet Cell Transplant
Drug · Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Miami, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 17, 2026, 9:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Raptiva and Sirolimus in Islet Transplantation for Type 1 Diabetes

NCT00672204
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
Allogeneic islets of Langerhans transplant, Raptiva, Sirolimus, anti-thymocyte globulin
Biological · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Oct 17, 2026, 9:15 AM EDT
Completed Phase 2 Interventional

Islet Cell Transplantation Alone in Patients With Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression

NCT00306098
View directory record Official record
Conditions
Diabetes Mellitus, Type I
Interventions
islets
Drug
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 17, 2026, 9:15 AM EDT
Completed Phase 1Phase 2 Interventional

Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus

NCT00501709
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Belatacept and Raptiva
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 17, 2026, 9:15 AM EDT
Completed Phase 3 Interventional

Efficacy of Islet After Kidney Transplantation

NCT00468117
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab, Etanercept, Allogenic human purified pancreatic islets
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 68 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
9
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 17, 2026, 9:15 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

NCT01206101
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 17, 2026, 9:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intra-Portal Alone Versus Intra- and Extra-Portal Transplantation of Pancreatic Islets After Total Pancreatectomy for Chronic Pancreatitis

NCT03779139
View directory record Official record
Conditions
Chronic Pancreatitis, Diabetes Mellitus, Islet Cell Transplantation
Interventions
Intrahepatic islets and islets in the omental pouch, Intrahepatic islets alone, Normal Volunteers
Procedure · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 68 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 17, 2026, 9:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

NCT00679042
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islets of Langerhans transplantation
Biological
Lead sponsor
CellTrans Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 17, 2026, 9:15 AM EDT
Approved For Marketing No phase listed Expanded access

Islet Transplantation in Type I Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol

NCT03791567
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Donislecel (allogeneic islets of Langerhans for transplant)
Biological
Lead sponsor
CellTrans Inc.
Industry
Eligibility
18 Years to 75 Years
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 17, 2026, 9:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

MGA031, Sirolimus and Tacrolimus in Islet Transplantation

NCT00265473
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
Allogeneic Islets of Langerhans
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 17, 2026, 9:15 AM EDT